Roivant Sciences Ltd. (NASDAQ:ROIV) Receives $17.93 Consensus Target Price from Analysts

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have earned a consensus rating of “Buy” from the eight ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $17.93.

Several research firms recently weighed in on ROIV. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a report on Thursday, January 30th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a research note on Wednesday, November 13th.

Roivant Sciences Price Performance

Shares of Roivant Sciences stock opened at $10.70 on Tuesday. Roivant Sciences has a 1-year low of $9.69 and a 1-year high of $13.06. The business’s fifty day moving average price is $11.66 and its two-hundred day moving average price is $11.60. The company has a market capitalization of $7.79 billion, a P/E ratio of 1.89 and a beta of 1.25.

Insider Buying and Selling

In other news, Director Sciences Ltd. Roivant bought 16,845,010 shares of the company’s stock in a transaction dated Monday, January 13th. The shares were acquired at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the transaction, the director now directly owns 96,650,341 shares in the company, valued at approximately $1,933,006,820. The trade was a 21.11 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Eric Venker sold 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $11.28, for a total transaction of $1,128,000.00. Following the completion of the sale, the chief operating officer now owns 732,294 shares of the company’s stock, valued at approximately $8,260,276.32. This trade represents a 12.01 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,942,629 shares of company stock worth $23,034,486 in the last ninety days. 7.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Roivant Sciences

Large investors have recently added to or reduced their stakes in the company. Gladius Capital Management LP purchased a new position in shares of Roivant Sciences during the 3rd quarter valued at $35,000. US Bancorp DE grew its stake in Roivant Sciences by 146.5% in the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after purchasing an additional 1,948 shares in the last quarter. GAMMA Investing LLC increased its position in Roivant Sciences by 57.0% in the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after purchasing an additional 1,288 shares during the last quarter. Quarry LP purchased a new stake in shares of Roivant Sciences during the 2nd quarter worth about $53,000. Finally, Blue Trust Inc. raised its stake in shares of Roivant Sciences by 550.1% during the 4th quarter. Blue Trust Inc. now owns 7,879 shares of the company’s stock worth $91,000 after purchasing an additional 6,667 shares in the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.